Project Grant R61HL168750
Award Date
8/15/23
Completion Date
6/30/24
Dollars Obligated
$350K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Virginia, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI), through the Cardiovascular Diseases Research (CFDA 93.837) federal grant program, awarded a $1,249,317 Project Grant to Sanaheal Inc. for the development and validation of a "Hemostatic Bioadhesive Paste for Coagulation-Independent Rapid Control of Bleeding." The objective is to optimize and validate this hemostatic paste to meet FDA regulatory requirements in preparation for a future pivotal clinical trial and commercialization....
This $647,359 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the engineering of biomaterials with controlled biomolecule delivery for cardiovascular applications. The key products and services to be delivered include: Efficient and sustainable delivery of microRNA-145 from a novel biomaterial (PVA-CDI immobilized aminated fucoidan, or PCAF) to smooth muscle cells to induce a contractile...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), supports the continued clinical development of a novel pleural and tracheal sealant. The $381,000 award to the University of Vermont will fund research to: 1) define optimal manufacturing, sterilization, and storage conditions for the sealant patch; 2) further evaluate the long-term safety and efficacy of the sealant in animal models...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is funding the development of a novel, injectable biomaterial hydrogel to enable sustained delivery of the therapeutic protein neuregulin-1 (NRG1) to the myocardium for the treatment of myocardial infarction (MI). The $769,789 award to The Leland Stanford Junior University will support a 4-year research project to design and evaluate the...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $695,865.00 to the University of Pittsburgh to develop an optimized, minimally invasive strategy to treat ischemic cardiomyopathy (ICM). The key products and services to be delivered include: Evaluating the functional, geometric, and histopathologic effects of injecting three different thermoresponsive hydrogel formulations into an ICM...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,989,548.00 to Cerulean Scientific Inc., a small disadvantaged business in Durham, North Carolina, to develop a slippery, omniphobic coating for peripheral vascular grafts (PVGs). The goal is to investigate the ability of the tethered liquid perfluorocarbon (TLP) coating to resist occlusion, thrombus formation, and biofilm formation on PVGs, which are a common...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $306,102 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Peca Labs Inc. on August 1, 2025. The grant funds the development and feasibility testing of a novel, fully-polymeric, biomimetic prosthetic mitral valve constructed from clinically-proven materials. The goal is to improve durability, performance, and overall outcomes compared to current biologic and mechanical valve options. Specific aims include...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program provides $385,381 to Trustees of Tufts College, a private research university, to develop and evaluate injectable, elastic silk-cardiac extracellular matrix (CECM) composite hydrogels for stabilizing the ventricular wall and promoting cardiac tissue repair following myocardial infarction. The goal is to create biomaterials that can dynamically mimic...
This Cooperative Agreement award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program provides $1,250,000 in funding to Biodevek Inc., a Boston-based small business, to develop a sprayable hydrogel sealant for managing gastrointestinal (GI) lesions and bleeding. The project aims to create the first minimally invasive, bio-adhesive hydrogel solution that can provide sustained lesion protection and hemostasis, with the potential to...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop a flexible bioelectronic microarchitecture that integrates a capillary-like delivery network and a tissue-like sensing network to improve cardiac tissue engineering. The $488,026 award supports the creation of a system that can efficiently deliver media and provide real-time physiological feedback to enhance the development of...